Should I Buy GPAT? GPAT 2026 Analysis

Should You Buy GP-Act III Acquisition Corp (GPAT) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

10.760

1 Day change

0.28%

52 Week Range

10.770

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient trader: price is sitting right at/near short-term resistance with limited immediate upside before a likely pause.
Trend is bullish, but the setup is not offering a clean, high-conviction entry today (no proprietary buy signals; momentum is getting stretched).
Intellectia Proprietary Trading Signals
AI Stock Picker: no signal on given stock today.
SwingMax: No signal on given stock recently.
With no news/catalysts and no notable smart-money activity, GPAT looks more like a low-volatility hold/skip than a must-buy now.

Technical Analysis

Trend: Bullish structure (SMA_5 > SMA_20 > SMA_200) indicates an established uptrend.
Momentum: MACD histogram is positive and expanding (0.00186), supporting continuation—but not a fresh breakout signal.
RSI(6): 68.38 (upper-neutral, close to overbought), suggesting upside may be limited near-term without consolidation.
Key levels: Pivot ~10.743; immediate resistance R1 10.762 / R2 10.774; supports S1 10.724 / S2 10.712.
Practical read: at ~10.74–10.74+ post-market, you’re buying into nearby resistance rather than a pullback.

Positive Catalysts

- Technical backdrop is constructive (bullish moving averages + positive MACD).
- Pattern-based projection provided: estimated 80% chance of gains of ~1.22% next day, ~4.12% next week, ~7.5% next month.
- No reported negative news flow in the last week.

Neutral/Negative Catalysts

- No identifiable event-driven catalysts ("No news in recent week"); lacking a trigger to expand volume/volatility.
- RSI is elevated (near overbought) while price is near immediate resistance (R1/R2), reducing risk-reward for an "enter now" trade.
- Trading trends: Hedge funds neutral (no significant quarterly trend) and insiders neutral (no significant monthly trend).

Financial Performance

Latest quarter: 2025/Q3.
Revenue: 0 (0.00% YoY) — no operating growth signal in the snapshot.
Net income: 3,105,859 (-15.06% YoY) — declining.
EPS: 0.09 (-10.00% YoY) — declining.
Overall: snapshot shows weakening profitability metrics YoY, with no revenue growth indicated.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating/price target update data provided in the dataset.
Wall Street pros/cons view cannot be reliably summarized from the given inputs (no ratings/targets to assess momentum or dispersion).
Politicians/congress: No recent congress trading data available (last 90 days).

Analyst Rating

Wall Street analysts forecast GPAT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GPAT is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Buy

Hold

Sell

Current: 10.730

Low

Averages

High